GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Intrinsic Value: Projected FCF

BriaCell Therapeutics (BriaCell Therapeutics) Intrinsic Value: Projected FCF : $-6.87 (As of Apr. 29, 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-29), BriaCell Therapeutics's Intrinsic Value: Projected FCF is $-6.87. The stock price of BriaCell Therapeutics is $2.17. Therefore, BriaCell Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for BriaCell Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of BriaCell Therapeutics was 61.92. The lowest was 11.47. And the median was 36.70.

BCTX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.32
* Ranked among companies with meaningful Price-to-Projected-FCF only.

BriaCell Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for BriaCell Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Intrinsic Value: Projected FCF Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.59 -32.83 -0.58 -2.51 -5.38

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.74 -4.58 -5.38 -5.11 -6.76

Competitive Comparison of BriaCell Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, BriaCell Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Price-to-Projected-FCF falls into.



BriaCell Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get BriaCell Therapeutics's Free Cash Flow(6 year avg) = $-10.75.

BriaCell Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jan24)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-10.7472+-8.073/0.8)/15.982
=-7.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (NAS:BCTX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

BriaCell Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.17/-7.0334359074054
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus

BriaCell CEO Letter to Shareholders

By Stock market mentor Stock market mentor 01-24-2023

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

By sperokesalga sperokesalga 02-10-2023